One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

KEY TAKEAWAYS Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

Novo Nordisk A/S rose the most in a month after an experimental shot delivered as much as 22% weight loss in an early-stage ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...